Repurposing fostamatinib to combat SARS-CoV-2-induced acute lung injury.
File(s)
Author(s)
Tabassum, Neha
Zhang, Hua
Stebbing, Justin
Type
Journal Article
Abstract
A screen by Kost-Alimova et al.1 suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
Date Issued
2020-11-17
Date Acceptance
2020-11-01
Citation
Cell Reports Medicine, 2020, 1 (8), pp.1-2
ISSN
2666-3791
Start Page
1
End Page
2
Journal / Book Title
Cell Reports Medicine
Volume
1
Issue
8
Copyright Statement
© 2020 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
License URL
Sponsor
Imperial College Healthcare NHS Trust- BRC Funding
National Institute for Health Research
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/33225317
PII: S2666-3791(20)30189-0
Grant Number
RDB01 79560
NIHR-RP-011-053
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2020-11-17